The cannabinoid receptor 1 (CNR1), also known as CB1. is a G protein-coupled receptor primarily involved in mediating the effects of endocannabinoids, such as anandamide and 2-arachidonoylglycerol. It is abundantly expressed in the central nervous system (CNS), particularly in regions regulating cognition, emotion, and pain perception, but also found in peripheral tissues like the liver, adipose, and immune cells. CNR1 antibodies are essential tools for studying the receptor's expression, localization, and functional roles in physiological and pathological processes. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate CNR1 distribution in tissues or its alterations in diseases such as obesity, neurodegenerative disorders, and addiction. Developing specific CNR1 antibodies has been challenging due to the receptor's structural similarity to other GPCRs and low antigenicity of certain epitopes. Nonetheless, well-validated antibodies enable research into CNR1 signaling pathways, ligand-receptor interactions, and the development of therapeutics targeting the endocannabinoid system. Recent studies also explore CNR1's role in metabolic regulation and neuroinflammation, highlighting its therapeutic potential. Proper antibody validation, including knockout controls and functional assays, remains critical to ensure specificity and reliability in experimental outcomes.